(Q24816510)

5 July 2017

1 reference

A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis (English)

1 reference

5 July 2017

0 references

0 references

1 reference

1 reference

Christian J Wiedermann

series ordinal

1

1 reference

5 July 2017

Nicole C Kaneider

series ordinal

2

1 reference

5 July 2017

language of work or name

English

0 references

publication date

14 October 2005

1 reference

5 July 2017

published in

BMC Emergency Medicine

1 reference

5 July 2017

volume

5

1 reference

5 July 2017

issue

1

0 references

page(s)

7

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

5 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

Drotrecogin alfa Eli Lilly.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

New strategies for clinical trials in patients with sepsis and septic shock

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis

28 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-227X-5-7

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-227X-5-7

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1266358

28 November 2018

Identifiers

DOI

10.1186/1471-227X-5-7

1 reference

Dimensions Publication ID

5 July 2017

0 references

1 reference

5 July 2017

1 reference